0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD30

CD30

CD30 Molecule Information

Name:Tumor necrosis factor receptor superfamily member 8
Target Synonym:TNFRSF8;Lymphocyte activation antigen CD30;D1S166E;CD30L receptor;Tumor necrosis factor receptor superfamily member 8;CD30 ;Ki-1 antigen;CD_antigen=CD30
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Approved

CD30 Protein Product ListCompare or Buy

CD30 Molecule Synonym Name

TNFRSF8,CD30,D1S166E,Ki-1

CD30 Molecule Background

Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

CD30 References

CD30 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Brentuximab vedotin SGN-35; SGN-30; cAC-10; SGD-1010; cAC10-vcMMAE; cAC10-Val-Cit-MMAE,SGN35,SGN30,SGD1010 Approved Seattle Genetics, Millennium Pharmaceutical ADCETRIS fda Systemic anaplastic large cell lymphoma, Hodgkin lymphoma SEATTLE GENETICS 2011-08-19 Mantle cell lymphoma (MCL), Systemic anaplastic large cell lymphoma, Mycosis fungoides, Hodgkin lymphoma Details

CD30 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) Phase Ⅱ UNC Lineberger Comprehensive Cancer Center Lymphoproliferative disease, Lymphoma, Non-Hodgkin's lymphoma (NHL), Immunological disorders Details
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) Phase Ⅰ Immune Cell, Weifang People's Hospital Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma Details
Anti-CD30 monoclonal antibody BerH2 Phase Ⅰ Nonindustrial source, Medac Hodgkin lymphoma Details
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) CBM-C30.1; CAR30-NKT; CD30ScFv-CD8-CD137-CD3zeta,CBM C30.1; CAR30 NKT Phase Ⅱ General Hospital of the People's Liberation Army, Cellular Biomedicine Group Hodgkin lymphoma Details
Anti-CD30 CAR T-cell therapy (University of Cologne) Preclinical University of Cologne Cancer Details
Anti-CD30 CAR-T cell therapy (National Cancer Institute) Hu30-CD28z Phase Ⅰ National Cancer Institute Lymphoma Details
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) Phase Ⅰ Wuhan Bio-Raid Biotechnology Lymphoproliferative disease Details
XmAb-2513 XmAb-2513 Phase Ⅰ Xencor T-cell lymphoblastic lymphoma, Hodgkin lymphoma Details
Iratumumab MDX-060; MAb-5F11; anti-CD30 Phase Ⅱ Medarex Lymphoma, Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma Details
HRS-3/A9 HRS-3/A9; Anti-CD16/CD30 BiMAb,HRS 3/A9; Anti CD16/CD30 BiMAb Phase Ⅱ University of Saarland, Biotest Hodgkin lymphoma Details
CD30.CAR CD30.CAR; H-27721 Phase Ⅰ Baylor College of Medicine, bluebird bio Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma Details
Anti-CD64-anti-CD30 bispecific monoclonal antibody (Medarex) Phase Ⅰ Medarex Hodgkin lymphoma Details
Anti-CD16-anti-CD30 monoclonal antibody Phase Ⅱ Biotest Hodgkin lymphoma Details
AFM-13 AFM-13 Phase Ⅱ University of Texas M. D. Anderson Cancer Center, Affimed Mycosis fungoides, Peripheral T cell lymphoma (PTCL), Hodgkin lymphoma Details
EBV-specific-CAR.CD30 EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs Phase Ⅰ Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma Details
MDX-1401 MDX-1401 Phase Ⅰ Medarex Hodgkin lymphoma Details
Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 Phase Ⅰ Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai Jiaolian Anaplastic large cell lymphoma (ALCL), Cutaneous T cell lymphoma (CTCL), Hodgkin lymphoma Details

This web search service is supported by Google Inc.

totop